EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS
2018 RD 3 INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM
DECEMBER 13-15, 2018 NEW YORK, NY
MOUNTSINAIUROLOGYCME.ORG
HIGHLIGHTS • Over 100 world-renowned faculty • Engaging point-counterpoint debates and • Live 3D surgical demonstrations, including panel discussion prostate, kidney, bladder procedures • Global exposure with international web streaming of select sessions and events TOPIC AREAS
• Epidemiology and Early Diagnosis of Prostate Cancer
• Staging, Imaging, and Genomics
• Management of Very Low Risk and Low Risk Prostate Cancer
• Focal Therapy
• Surgical Treatment of Intermediate Risk Prostate Cancer
• Sexual Health Following Prostatectomy
• Radical Prostatectomy
• Immunotherapy and Tumor Microenvironment
• Upper Tract Disease
• Partial Nephrectomy
• Kidney Cancer
• PARP Inhibitors in Prostate Cancer DECEMBER 13 – 15, 2018 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS
DIRECTOR: ASH TEWARI, MBBS MCH Professor and Chairman of the Department INVITATION of Urology Department of Urology TO EXHIBIT/SPONSOR [email protected] CO-DIRECTOR: Dear Industry Colleagues: KETAN BADANI MD Professor of Urology and Vice Chairman of the Department of Urology On behalf of the Department of Urology at the Icahn School of Medicine at Department of Urology Mount Sinai in New York City, I am thrilled to invite you to participate in the Third [email protected] International Prostate Cancer and Urologic Oncology Symposium set for December
13-15, 2018 in New York! This year’s program is our most innovative yet, complete PLANNING COMMITTEE: with over 100 world-renowned experts who will provide in-depth training on cutting- NINA BHARDWAJ MD, PhD edge medical advances and ground-breaking treatment approaches for prostate, Professor of Medicine, Hematology, kidney, bladder, and renal cell cancers. There will also be a unique focus this year and Medical Oncology Department of Medicine, Hematology, and on critical issues in immuno-oncology and sexual health, as well as multiple live Medical Oncology surgeries and focused demonstrations. Ranked among the nation’s best for Urology [email protected] in the “Best Hospitals” issue of U.S. News & World Report, the physicians of Mount CARLOS CORDON-CARDO MD, PhD Sinai Urology are leaders in robotic surgery and minimally invasive procedures to Professor and Chairman treat prostate, kidney, and bladder cancers. Join the Mount Sinai Department of of the Department of Pathology Urology for an interactive symposium with 3D demonstrations of the latest robotic Department of Pathology surgery techniques for prostate, kidney and bladder cancer. Directed by the world’s [email protected] leading robotic experts and taught by an internationally renowned faculty, attendees MATTHEW GALSKY MD gain emerging and practical tools to optimize their robotic surgery skills. We are Professor of Medicine, Hematology, and Medical Oncology also on the forefront of diagnosis and treatment for urinary tract conditions, kidney Department of Medicine, Hematology, and stones, infertility, erectile dysfunction, female pelvic medicine, and pediatric urologic Medical Oncology conditions. [email protected] MANTU GUPTA MD As you will see in the enclosed Partnership Prospectus, we are offering several Professor of Urology sponsorship and exhibitor opportunities for this year’s program, including both Department of Urology traditional lunch product theatres and new, destination dinners, to help you gain [email protected]
access to, and inform, symposium attendees about your company, your research ADAM MARGOLIN PhD development program and your marketed products. We expect over 500 attendees Professor and Chairman of the Department of Genetics at this year’s program, including physicians, nurses, pharmacists, and researchers, all and Genomic Science of whom will be actively engaged in discussions across the prostate and urological Department of Genetics and cancer landscape. Thus, this year’s innovative lunch and dinner events, highly visible Genomic Science corporate exposure options, additional networking opportunities, and the larger [email protected] and more diverse group of attendees will undoubtedly result in a valuable, and WILLIAM OH MD memorable experience for you as our key partner. Professor of Medicine, Hematology, and Medical Oncology Department of Medicine, Hematology, and Affiliating with the Third International Prostate Cancer and Urologic Oncology Medical Oncology Symposium is the most direct route in meeting and sharing your products with some [email protected] of the most well-known, respected health care providers and decision makers in the MICHAL PALESE MD urologic community. As an essential part of the symposium, you will be able to make Professor of Urology invaluable connections with key opinion leaders, academic researchers and other Department of Urology industry stakeholders as we continue the tradition of advancing the level of science [email protected]
and quality of care in prostate and urologic oncology. ERIC SCHADT PhD Dean of Precision Medicine, Professor of To this end, I invite you to review the attached Partnership Prospectus to learn Genetics and Genomic Science more about the program and to find out how to reserve your prime exhibit space Department of Genetics today. More information can be found at mountsinaiurologycme.org. If you have and Genomic Science any questions, please contact Ms. Manbeena Anand at 310.247.3840 or via email [email protected] at [email protected]. We look forward to having you as our industry BACHIR TAOULI MD partner for this year’s program! Professor of Radiology Department of Radiology Sincerely, [email protected]
Ash Tewari, MBBS, MCh PROFESSOR, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI KYUNG HYUN KIM, MD, CHAIR OF THE DEPARTMENT OF UROLOGY CHAIR, MILTON AND CARROLL PETRIE DEPARTMENT OF UROLOGY, MOUNT SINAI HEALTH SYSTEM MOUNTSINAIUROLOGYCME.ORG | 3 • 2016 • • 2017 • • •• • • • • • • • • • • • • • FACULTY
Ronney Abaza MD, FACS Ohio Health Dublin Jonathan Haas MD NYU Winthrop Hospital Rajveer Purohit MD Mount Sinai -Department Methodist Hospital Mishop Han MD Johns Hopkins School of Urology Ketan Badani MD Mount Sinai - Department of Medicine Art Rastinehad DO Mount Sinai - Department of Urology Stefanie Hectors PhD Mount Sinai - Icahn School of Urology Christopher Barberie MD, PhD of Medicine Amanda Rhee MD Mount Sinai - Department Weill Cornell Medicine Ashok Hemal MD Wake Forest Baptist Health - of Anesthesiology, Perioperative & Pain Natan Bar-Chama MD Mount Sinai - Institute for Regenerative Medicine Medicine Department of Urology and Department of Michael Herman MD South Nassau Lee Richstone MD LIJ Medical Center Obstetrics, Gynecology, and Reproductive Communities Hospital Kenneth Rosenzweig MD Mount Sinai - Science Markus Hohenfellner MD University Department of Radiation Oncology Arie Belldegrun MD, FACS UCLA - Institute of of Witten - Department of Urology and Jaspreet Sandhu MD Memorial Sloan Urologic Oncology Pediatric Urology Kettering Thomas Bessede MD CHU Bicetre, Bicetre Jim Hu MD, MPH Weill Cornell Medicine Peter Scardino MD, FACS Memorial Sloan Pari-South University Jihad Kaouk MD Cleveland Clinic - Department Kettering Nina Bhardwaj MD, PhD Mount Sinai - of Urology Douglas Scherr MD Weill Cornell Medicine Department of Medicine, Hematology and Medical Oncology Steven Kaplan MD Mount Sinai - Department Howard Schiff MD Mount Sinai - Department of Urology of Urology Jerry Blaivas MD Mount Sinai - Department of Urology Deepak Kapoor MD Mount Sinai - Department Mark Schoenberg MD Albert Einstein College of Urology of Medicine Jeffrey Bockman PhD Defined Health Aaron Katz MD NYU Winthrop Hospital - Peter Schulam MD, PhD Yale Cancer Center Giuseppe Carrieri MD Department of Urology Department of Urology University of Foggia John Sfakianos MD Mount Sinai - Department Isaac Kim MD, PhD Rutgers - Cancer Institute of of Urology Peter Carroll MD, MPH UC San Francisco - New Jersey Department of Urology Neal Shore FACS, MD Atlantic Urology Clinics Joseph Kim MD Yale School of Medicine Brian Chapin MD University of Texas - Alan Sim MD Mount Sinai - Department Department of Urology, Division of Surgery Alexander Kirschenbaum MD Mount Sinai - of Anesthesiology, Perioperative & Pain Department of Urology Medicine Philippa Cheetham MD, FRCS (Urol) Mount Sinai - Department of Medicine Badrinath Konety MD, MBA University of Susan Slovin MD, PhD Memorial Sloan Kettering Minnesota - Department of Urology Arul Chinnaiyan MD, PhD University of Michigan Prasanna Sooriakumaran MD, PhD, FRCSUrol, FEBU • • • • •- Michigan • Center • for Translational• • Pathology• •Natasha • Kyprianou• • MD University• of Kentucky University of Oxford - Nuffield Department - College of Medicine of Surgical Sciences Ralph Clayman MD UC Irvine Jaime Landman MD UC Irvine Health Rene Sotelo MD UC Southern California Jonathan Coleman MD Memorial Sloan Kettering Vincent Laudone MD Michael Stifleman MD Hackensack University Memorial Sloan Kettering Medical Center Justin Collins MBChB, MD, FRCS Karolinska Institute Hugh Lavery MD Mount Sinai - Department Chandru Sundaram MD Indiana University - of Urology 2018School of Medicine Michael Cookson MD University of Oklahoma - Department of Urology David Lee MD, FACS Penn Presbyterian Medical Atsushi Takenaka MD, PhD Tottori University - Center - Division of Urology Division of Urology Carlos Cordon-Cardo MD, PhD Mount Sinai - Department of Pathology Herbert Lepor MD NYU Langone Health Samir Taneja MD NYU Langone Health Fabrizio Dal Moro MD, FEBU University of Bobby Liaw MD Mount Sinai - Department of Bachir Taouli MD Mount Sinai - Department Padova - Department of Surgery, Oncology, Medicine, Hematology and Medical Oncology of Radiology and Gastroenterology Daniel Lin MD University of Washington - Ash Tewari MBBS, MCh Mount Sinai - John Denstedt MD, FRCSC, FACS, FCAHS Western Department of Urology Department of Urology University - Department of Urology Ravi Madan MD National Cancer Institute Che-kai Tsao MD Mount Sinai - Department of Michael Droller MD Mount Sinai - Department Alberto Martini MD Mount Sinai - Department Medicine, Hematology and Medical Oncology of Urology of Urology/Vita-Salute San Raffaele Robert Valenzuela MD Mount Sinai - Christopher Evans MD, FACS UC Davis - University Department of Urology Department of Urology Reza Mehrazin MD Mount Sinai - Department Arnauld Villers MD, PhD University of Lille - Daniel Eun MD Temple University - Lewis Katz of Urology Urology Department School of Medicine Mani Menon MD Henry Ford Health System Nikhil Waingankar MD Mount Sinai - Bishoy Faltas MD Weill Cornell Medicine Nihal Mohamed PhD Mount Sinai - Department Department of Urology Gerardo Fernandez MD Mount Sinai - of Urology Gerald Wang MD, FACS Weill Cornell Medicine Department of Pathology Francesco Montorsi MD Vita-Salute San Wei-Chun (Jim) Weng MD Division of Daniel Gainsburg MD Mount Sinai - Raffaele University Urology, Department of Surgery, Tung’s Department of Anesthesiology, Perioperative Alex Mottrie MD OLV Hospital - Urology Taichung MetroHarbor Hospital & Pain Medicine Robert Motzer MD Memorial Sloan Kettering Peter Wiklund MD, PhD Karolinska Institutet Matthew Galsky MD Mount Sinai - Department of William Oh MD Mount Sinai - Department of Jorn Witt MD St. Antonius Hospital Gronau Medicine, Hematology and Medical Oncology Medicine, Hematology and Medical Oncology Ofer Yossepowitch MD Tel Aviv Sourasky Reza Ghavamian MD Northwell Health Dolan Aria Olumi MD Harvard Medical School Medical Center Family Health Center Sait Ozturk PhD Mount Sinai - Department of Michael Zelefsky MD Memorial Sloan Sacha Gnjatic PhD Mount Sinai - Icahn School Oncological Sciences Kettering of Medicine Michael Palese MD Mount Sinai - Department Alvin Goh MD Memorial Sloan Kettering of Urology Erik Goluboff MD Mount Sinai - Department Dipen Parekh MD University of Miami Health of Urology System Markus Graefen University Hospital Hamburg John Kellog Parsons MD UC San Diego Health Neil Grafstein MD Mount Sinai - Department Daniel Petrylak MD Yale Cancer Center of Urology Francesco Porpiglia MD University of Turin Nate Gross MD Doximity James Porter MD Swedish Urology Group James Gulley MD, PhD National Cancer Institute Isaac Powell MD Wayne State University Mantu Gupta MD Mount Sinai - Department of Urology MTSINAIUROLOGYCME.ORG | 5 THIRD INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM • DECEMBER 13 – 15, 2018 NEW YORK, NY
The Third International Prostate Cancer and Urologic
Oncology Symposium offers industry sponsors an exclusive
opportunity to interact with and educate clinicians on the latest
medical techniques and products. By partnering with the Icahn
School of Medicine at Mount Sinai hospital, your company can
have unprecedented access to, and visibility from, attendees and
faculty through a wide range of custom sponsorship packages,
including strategic placement of corporate logos, engaging
exhibitor booths, and innovative product theatres.*
*Corporate functions may not be held concurrent with official symposium/congress’ scientific or social functions. Any function, regardless of size and location, must be approved by the course’s industry relations department.
6 | MOUNTSINAIUROLOGYCME.ORG DECEMBER 13 – 15, 2018 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS
OPPORTUNITIES FOR SPONSORSHIP
SPONSORSHIP PACKAGES
REGENT LEVEL $30,000 FELLOW LEVEL $20,000 This elite level of sponsorship is one of the most visible ways to support the This level of sponsorship clearly positions your company as a leader in the field Third International Prostate Cancer and Urologic Oncology Symposium and and the package features are designed to attract and engage a high number of solidifies your position as a true partner to the Icahn School of Medicine at the attendees. Mount Sinai Hospital. Among other benefits, this level of sponsorship includes Key benefits include consistent placement of logo throughout entire exhibitor branded meeting lanyards, a Symposium WiFi access key or an advertisement space, a targeted advertisement in the symposium handouts, and a choice in our Robotic Urology App, and a prime location to feature your custom exhibit. exhibitor location. • Premium 7’ by 20’ exhibitor booth, including a draped table and chairs • Deluxe 6’ by 10’ exhibitor booth, including a draped table and chairs • Choice of one additional value-added promotional opportunity: Branded • Half-page presence included in symposium handouts Meeting Badge Lanyards, Symposium WiFi Access Key or Robotic Urology App Advertisement • Company logo featured on conference website, invitations, symposium handouts, and all event signage in the exhibit hall • Full-page presence included in symposium handouts • Company logo displayed on all floor arrows directing participants in the • Company logo prominently featured on conference website, invitations, exhibit hall symposium handouts and all event signage in the exhibit hall • 8 complimentary all access badges • 12 complimentary all access badges • 2 complimentary tickets to Welcome Gala, an exclusive invitation-only event • 4 complimentary tickets to the Welcome Gala, an exclusive invitation-only event held on December 12, 2018 held on December 12, 2018.
PATRON LEVEL $10,000 ASSOCIATE LEVEL $5,000 This level of sponsorship offers you critical access to, and visibility from, This is our most basic level of sponsorship and includes the ability to showcase program attendees through our standard sponsorship offerings. your company and/or products through standing banners or posters in the main exhibit hall. Key benefits include a targeted advertisement in the symposium handouts, consistent placement of company logo throughout symposia signage, and a • 1 designated display space to accommodate a poster or banner (Banners must be standard exhibitor booth. floor standing and be 36” by 96”)
• Standard 4’ by 75” exhibitor booth, including a draped table and chairs • 1 complimentary all access badge • Quarter-page presence included in symposium handouts • Company logo displayed on conference website, invitations, symposium handouts, and all event signage in the exhibit hall • 4 complimentary all access badges
MOUNTSINAIUROLOGYCME.ORG | 7 THIRD INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM • DECEMBER 13 – 15, 2018 NEW YORK, NY
OPPORTUNITIES FOR SPONSORSHIP
OTHER VALUE-ADDED SPONSORSHIP OPPORTUNITIES DINNER OUTING $45,000 COFFEE BREAKS $6,000 2 AVAILABLE 3 AVAILABLE This new offering for 2018 is designed to truly distinguish and highlight key This option allows you to sponsor a coffee break during the day with signage sponsors through a unique, off-site dinner. Conference attendees, faculty and acknowledging your sponsorship and support of the program placed within the other key stakeholders will enjoy an exclusive meal with our chairman, Dr. Ash exhibit hall. Days of break will be assigned on a first come, first served basis. Tewari, and the Symposium Planning Committee. In addition to recognition in all dinner print materials, your logo will also be featured on the evening menu, SYMPOSIUM BAGS $8,000 conference website, invitations, symposium handouts, and all event signage in 1 AVAILABLE the exhibit hall. This is an exclusive opportunity to have your company name and logo prominently displayed on the branded Symposium bag. This will guarantee attendee traffic to you PRODUCT THEATRE LUNCHEON $25,000 3 AVAILABLE in the exhibit hall as the bags will only be distributed in that area. This prime sponsorship offering includes a designated space and a non- competing timeslot for you to highlight your data, products and services. Key benefits include a distinguished private space, basic audio-visual package, and targeted product theatre promotion to our attendees through the symposium handouts and signage. Lunch will be provided.
SPONSORSHIP INFORMATION
MEETING DETAILS PAYMENT, CANCELLATIONS AND REFUNDS • The Third International Prostate Cancer and Urologic Oncology Symposium • Payment should be made as soon as possible to secure the exhibit space (on • Thursday, December 13 – Saturday, December 15, 2018 a first come, first served basis). It is due no later than October 15, 2018. All cancellations must be in writiang. The following refund schedule applies: • The Mount Sinai Hospital Stern Auditorium • Cancellations requested after November 1, 2018: No portion of the original 1 Gustave L. Levy Place exhibit fee will be refunded. New York, NY 10029-6574 CONTACT INFORMATION For more information about supporting the Third International Prostate Cancer • Over 100 world-renowned faculty and Urologic Oncology Symposium, please contact: • Over 500 attendees EXHIBIT SCHEDULE Sponsorship Opportunities/Educational Grants: • Times are subject to change without notice. Insyght Interactive, Inc. • Exhibit Set-Up: Thursday, December 13, after 9:00 pm Ms. Manbeena Anand 310.247.3840 x 2010 • Exhibit Hours [email protected] Friday, December 14, 7:00 am – 6:00 pm Saturday, December 15, 7:00 am – 6:00 pm On-Site Meeting Support & Exhibit Coordination: Exhibit Teardown: Saturday, December 15, after 6:00 pm Gaffney Events, LLC Ms. Jennifer Berens 425.442.1314 [email protected] 8 | MOUNTSINAIUROLOGYCME.ORG DECEMBER 13 - 15, 2018 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS
SPONSORSHIP FORM
THIRD ANNUAL INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM Mount Sinai Hospital December 13–15, 2018 mountsinaiurologycme.org Company Name (As it should appear on printed material)
Contact Person (individual to whom all exhibitor information will be forwarded) Title
Street Address
City State Zip
Telephone Fax Email
Product
BADGES (please look at partnership opportunity descriptions to determine your badge allotment)
Representative Name (First, Last) Title Email Address Phone
PARTNERSHIP LEVELS
Regent Level $30,000 Patron Level $10,000 Dinner Outing $45,000 (2 Available) Coffee Breaks $6,000 (3 Available) Fellow Level $20,000 Associate Level $5,000 Product Theatre Luncheon $25,000 (3 Available) Symposium Bags $8,000 (1 Available)
PAYMENT
Make checks payable to: Gaffney Events Educational Trust EIN #: 47-3109028 Mail: Gaffney Events, 27322 NE 143rd Place, Duvall, WA 98019 Fax: (425)788-0668 Email: [email protected] MTSINAIUROLOGYCME.ORGPhone: (425) 442-1314 | 9
*For all sponsorship-related questions, please contact Ms. Manbeena Anand at 310.247.3840 or via email at [email protected]. THIRD INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM • DECEMBER 13 – 15, 2018 NEW YORK, NY THURSDAY, DECEMBER 13 MORNING AGENDA
7:00 am – 7:10 am Welcome and Introduction Ash Tewari, MBBS, MCh
The Hans E. Shapira Lecture 7:10 am – 7:40 am Peter Scardino, MD, FACS Prostate Cancer: A Perspective; the Right Treatment for the Right Patient at the Right Time Epidemiology and Early Diagnosis of Prostate Cancer PANELISTS (Part 1) Guiseppe Carrieri, MD Ralph Clayman, MD, MBA Philippa Cheetham, MD, FRCS (Urol)
7:40 am – 8:00 am Epidemiology of Prostate Cancer Badrinath Konety, MD
SURGEON 8:00 am – 9:30 am 3D Live Surgery: Robot Assisted Radical Prostatectomy Ash Tewari, MBBS, MCh
MODERATORS Ketan K. Badani, MD, & Alberto Martini, MD
PANELISTS Francesco Montorsi, MD, Alex Mottrie, MD Peter Scardino, MD, FACS, Fabrizio Dal Moro, MD,FEBU
9:30 am – 9:45 am Management of Diet, Exercise on Prostate John Kellogg Parsons, MD
9:45 am- 10:00am Management of Inflammation in Prostate Cancer Bachir Taoli, MD
10:00 am – 10:10 am Q&A Epidemiology and Early Diagnosis of Prostate Cancer, Part 1
Coffee with Experts: Deepak Chopra, MD 10:10 am-10:40 am Impact of Mindfulness and Meditation on Prostate Cancer Ash Tewari MBBS, MCh
10:40 am – 10:50 am Q&A Coffee with Experts
10:50 am – 11:00 am Biomarkers in Prostate Cancer Christopher Evans MD, FACS
11:00 am – 11:15 am Imaging in Prostate Cancer Art Rastinehad, DO
11:15 am – 11:25 am Introduction to Sit-Down MRI Trial Ash Tewari, MBBS, MCh
11:25 am – 11:40 am Targeted-Biopsy Techniques Sameer Taneja, MD
When to Skip Biopsy 11:40 am – 11:50 am Arnauld Villers, MD, PhD Before Diagnosis, During AS, Follow-up of FT
11:50 am – 12:00 pm How Has the Task Force Hurt Cancer Screening? Jim Hu, MD, MPH
12:00 pm – 12:10 pm Q&A Epidemiology and Early Diagnosis of Prostate Cancer, Part 2
10 | MTSINAIUROLOGYCME.ORG DECEMBER 13 – 15, 2018 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS THURSDAY, DECEMBER 13 AFTERNOON AGENDA
12:10 pm – 1:10 pm Lunch Sponsor TBD
PANELISTS Staging, Imaging, and Genomics Chris Barberie, MD, Alex Mottrie, MD, MBA, Francesco Montorsi,MD, & Kenneth Rosenzweig, MD
1:10 pm – 1:40 pm In Search of a Man Eater Ash Tewari, MBBS, MCh
1:40 pm – 2:10 pm Genomic Landscape of Prostate Cancer Arul Chinnaiyan, MD, PhD
Current Status of Nomograms and Imaging Markers in 2:10 pm – 2:20 pm Chris Barberie, MD Prostate Cancer
2:20 pm – 2:35 pm Estimation of Prostate Cancer Aggressiveness with mpMRI Bachir Taouli, MD
2:35 pm – 2:50 pm Genomics in Prostate Cancer Christopher Evans MD, FACS
2:50 pm – 3:00 pm Q&A Staging, Imaging, and Genomics
DEBATE DEBATORS 3:00 pm – 3:30 pm Imaging is More Appropriate for Identifying Art Rastinehad, DO Unfavorable Pathology in Early Prostate Cancer Genomics is Best for Identifying Eric Klein, MD Unfavorable Pathology in Early Prostate Cancer
PANELISTS Management of Very Low Risk and Low Risk Prostate Atsushi Takenaka, MD, PhD Cancer Lee Richstone, MD John Denstedt, FRCSC, FACS, FCAHS
Cost Effective Diagnostic and Active Surveillance 3:30 pm – 3:45 pm Badrinath Konety, MD Strategies for Prostate Cancer
Outcome of Delayed Radical Prostatectomy 3:45 pm – 4:00 pm in Those Managed Initially with Active Surveillance Peter Carroll, MD, MPH
4:00 pm – 4:10 pm Management of BPH in Active Surveillance Patients Steven Kaplan, MD
4:10 pm – 4:20 pm Q&A Management of Very Low Risk and Low Risk Prostate Cancer
Best Treatment for Aggressive Prostate Cancer PANELISTS William Oh, MD Bobby Liaw, MD Daniel Lin, MD Peter Scardino, MD, FACS State of ART Lecture 4:20 – 4:50 pm Arie Belldegrun, MD, FACS Innovative Drug Development and the Academic Urologic Oncologist: A Personal Experience
MOUNTSINAIUROLOGYCME.ORG | 11 THIRD INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM • DECEMBER 13 – 15, 2018 NEW YORK, NY THURSDAY, DECEMBER 13 LATE AFTERNOON & EVENING AGENDA
PANELISTS Focal Therapy Art Rastinehad, DO Jonathan Coleman, MD Aaron Katz, MD Jim Hu, MD
4:50 pm – 5:05 pm Focal Therapy: Is it Ready for Prime Time? Herbert Lepor, MD
5:05 pm – 5:15 pm Focal Therapy for Prostate CancER Art Rastinehad, DO
5:15 pm – 5:25 pm Partial Gland Ablation and Focal Therapy Johnathan Coleman, MD for Prostate Cancer
5:25 pm – 5:35 pm The Role of Salvage Cryotherapy and the Outcomes Aaron Katz, MD
5:35 pm – 5:45 pm Precision Focal Prostatectomy Mani Menon, MD
5:45 pm – 5:55 pm Complications of Focal Therapy Rene Javier Sotelo, MD
PANELISTS Surgical Treatment of Intermediate Risk Prostate Cancer Markus Hohenfellner, MD, Prasanna Sooriakumaran, MD, PhD, FRCS Urol, FEBU
5:55 pm – 6:05 pm QOL Comparison Between Open vs Robotic Prostatectomy Mishop Han, MD
6:05 pm – 6:15 pm Metastatic Hormone Sensitive Prostate Cancer: Michael Cookson, MD What the Urologist Needs to Know
6:15 pm – 6:30 pm New Anatomy of Prostate for Robotic Prostatectomy Ash Tewari, MBBS, MCh
6:30 pm – 6:40pm RARP: Surgical Steps for Better Oncological and Jorn Witt Functional Outcomes
6:40 pm – 6:50 pm Q&A: Surgical Treatment of Intermediate Risk Prostate Cancer
6:50 pm – 7:00 pm Conclusion Ash Tewari, MBBS, MCh
12 | MTSINAIUROLOGYCME.ORG DECEMBER 13 – 15, 2018 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS THURSDAY, DECEMBER 13 AFTERNOON BREAKOUT SESSION: IMMUNOTHERAPY & TUMOR MICROENVIRONMENT, PART I MODERATORS: NINA BHARDWAJ, MD, PHD AND ARIE BELLDEGRUN, MD, FACS I
Cancer Immunotherapy and Targeting Innate Immune 1:10 pm – 1:20 pm Nina Bhardwaj, MD, PhD Cells
1:20 pm – 1:23 pm Q&A Cancer Immunotherapy and Targeting Innate Immune Cells
1:23 pm – 1:33 pm Prostate Cancer Radiomics Study Stefanie Hectors, PhD
1:33 pm – 1:36 pm Q&A (Prostate Cancer Radiomics)
1:36 pm – 1:46 pm Targeting DNA Repair Deficiency in Prostate Cancer Joseph Kim, MD
1:46 pm – 1:49 pm Q&A Targeting DNA Repair Deficiency in Prostate Cancer
1:49 pm – 1:59 pm PRINT Study Discussion Bobby Liaw, MD
1:59 pm – 2:02 pm Q&A (PRINT Study Discussion)
Variable Expression of 5-Alpha Reductase 2 in BPH 2:02 pm – 2:12 pm and Advanced Prostate Cancer: Opportunities for Aria Olumni, MD Personalized Care Variable Expression of 5-Alpha Reductase 2 in BPH and Advanced Prostate Cancer: 2:12 pm – 2:15 pm Q&A Opportunities for Personalized Care
2:15 pm – 2:25 pm Combination Immunotherapy Strategies Ravi Madan, MD
2:25 pm – 2:28 pm Q&A Combination Immunotherapy Strategies
2:28 pm – 2:38 pm A Pragmatic Approach to Radiation Strictures Jerry Blaivas, MD
2:41 pm – 2:51 pm Urethral Strictures Rajveer Purohit, MD
2:51 pm – 2:54 pm Q&A Management of Incontinence After Radiation or Surgery
2:54 pm – 3:04 pm Same Old Sling? The Evolution of Perineal Sling Surgery Neil Grafstein, MD for Treatment of Post-Prostatectomy Incontinence Q&A Same old Sling? The Evolution of Perineal Sling Surgery for Treatment of Post-Prostatectomy 3:04 pm – 3:07 pm Incontinence
3:07 pm – 3:17 pm Treatment of Male Hypogonadism Using Non-Testosterone Natan Bar-Chama, MD Therapies
3:17 pm – 3:20 pm Q&ATreatment of Male Hypogonadism Using Non-Testosterone Therapies
Complications of Robot-Assisted Laparoscopic Surgery 3:20 pm – 3:30 pm Daniel Gansburg, MD Distant from the Surgical Site
3:30 pm – 3:33 pm Q&A Complications of Robot-Assisted Laparoscopic Surgery Distant from the Surgical Site
3:33 pm – 3:43 pm Quality of Life After Urologic Cancer Nihal Mohammed, PhD
3:43 pm – 3:46 pm Q&A Quality of Life After Urologic Cancer
Advances in Artificial Intelligence Applied to Prostate 3:46 pm – 3:56 pm Gerardo Fernandez, MD Cancer
3:56 pm – 3:59 pm Q&A Advances in Artificial Intelligence Applied to Prostate Cancer
Treatment of Locally Recurrent Prostate Cancer 3:59 pm – 4:09 pm Johnathan Haas, MD after Whole Gland Cryotherapy using CyberKnife
4:09 pm – 4:12 pm Q&A Treatment of Locally Recurrent Prostate Cancer after Whole Gland Cryotherapy using CyberKnife
MOUNTSINAIUROLOGYCME.ORG | 13 THIRD INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM • DECEMBER 13 – 15, 2018 NEW YORK, NY FRIDAY, DECEMBER 14 MORNING AGENDA
7:00 am – 7:10 am Day Two Welcome Ash Tewari, MBBS, MCh
Radical Prostatectomy PANELISTS Arul Chinnaiyn, MD, PhD, Douglas Scherr, MD, Ofer Yossepowitch, MD, and Prasanna Sooriakumaran, MD, PhD, FRCS Urol, FEBU The Hans E. Shapira Lecture 7:10 am – 7:25 am Peter Scardino, MD, FACS Prostate Cancer: A Perspective; the Right Treatment for the Right Patient at the Right Time Epidemiology and Early Diagnosis of Prostate Cancer PANELISTS (Part 1) Guiseppe Carrieri, MD Ralph Clayman, MD, MBA Philippa Cheetham, MD, FRCS (Urol) 7:25 am – 7:35 am Epidemiology of Prostate Cancer Badrinath Konety, MD
Radical Prostatectomy in Oligometastatic Disease: Prasanna Sooriakumaran, MD, PhD, 7:35 am – 7:50 am Experience from the UK RCT TRoMbone FRCSUrol, FEBU
7:50 am – 8:00 am Break/Visit Exhibits John Kellogg Parsons, MD
SURGEON 8:00am – 9:30 am 3D Live Surgery: Robot Assisted Radical Prostatectomy Ash Tewari, MBBS, MCh
MODERATORS Ketan K. Badani, MD, & Alberto Martini, MD
PANELISTS Aerie Belldegrun, MD, FACS, Reza Ghavamian, MD Francesco Porpiglia, MD, and Michael Cookson, MD Role of Surgery in Advanced Disease 9:30 am – 9:40 am Vincent Laudone, MD and Salvage Lymph Node Dissections Management of Lymph Node Positive Prostate Cancer 9:40 am – 9:55 am and Neoadjuvant Systemic Therapy in Localized Prostate Brian Chapin, MD Cancer The Role Local Therapy in Oligo-Metastatic Prostate 9:55 am – 10:10 am Markus Graefen, MD Cancer Cytoreductive Radical Prostatectomy 10:10 am – 10:20 am Isaac Kim, MD, PhD in Men with M1a or M1b Disease
10:20 am – 10:35 am 3D Image Guided Surgery in Prostate Cancer: Francesco Porpiglia, MD From Cognitive to Augmented Reality Procedures
10:35 am - 10:45 am Outpatient Prostatectomy David Lee, MD, FACS
10:45 am – 11:00 am Retzius-Sparing Trans-Douglas Radical Prostatectomy Markus Hoenfellner, MD
11:00 am – 11:15 am Recent Advances in Prostate Anatomy Atsushi Takenaka, MD, PhD
A Novel Approach for Apical Dissection During Robot- 11:15 am – 11:30 am Alex Mottrie, MD Assisted Radical Prostatectomy: The “Collar” Technique Salvage vs Adjuvant RT After Prostatectomy, 11:30 am – 11:40 am Michael Herman, MD Including the Role of Genomic Testing
14 | MTSINAIUROLOGYCME.ORG DECEMBER 13 – 15, 2018 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS FRIDAY, DECEMBER 14 AFTERNOON AGENDA
11:40 am – 11:55 am Perennial Robotic Prostatectomy Jihad Kaouk, MD
11:55 am – 12:05 pm Q&A Radical Prostatectomy
12:05 pm – 1:05 pm Lunch Sponsor TBD
PANELISTS Staging, Imaging, and Genomics Chris Barberie, MD, Alex Mottrie, MD, MBA, Francesco Montorsi,MD, and Kenneth Rosenzweig, MD
1:10 pm – 1:40 pm In Search of a Man Eater Ash Tewari, MBBS, MCh
1:40 pm – 2:10 pm Genomic Landscape of Prostate Cancer Arul Chinnaiyan, MD, PhD
Current Status of Nomograms and Imaging Markers in 2:10 pm – 2:20 pm Chris Barberie, MD Prostate Cancer
2:20 pm – 2:35 pm Estimation of Prostate Cancer Aggressiveness with mpMRI Bachir Taouli, MD
2:35 pm – 2:50 pm Genomics in Prostate Cancer Christopher Evans MD, FACS
2:50 pm – 3:00 pm Q&A Staging, Imaging, and Genomics
DEBATE DEBATORS 3:00 pm – 3:30 pm Imaging is More Appropriate for Identifying Art Rastinehad, DO Unfavorable Pathology in Early Prostate Cancer Genomics is Best for Identifying Eric Klein, MD Unfavorable Pathology in Early Prostate Cancer Management of Very Low Risk and Low Risk Prostate PANELISTS Cancer Atsushi Takenaka, MD, PhD Lee Richstone, MD John Denstedt, FRCSC, FACS, FCAHS
3:30 pm – 3:45 pm Cost Effective Diagnostic and Active Surveillance Badrinath Konety, MD Strategies for Prostate Cancer Outcome of Delayed Radical Prostatectomy 3:45 pm – 4:00 pm Peter Carroll, MD, MPH in Those Managed Initially with Active Surveillance
4:00 pm – 4:10 pm Management of BPH in Active Surveillance Patients Steven Kaplan, MD
4:10 pm – 4:20 pm Q&A Management of Very Low Risk and Low Risk Prostate Cancer
PANELISTS Best Treatment for Aggressive Prostate Cancer William Oh, MD Bobby Liaw, MD Daniel Lin, MD Peter Scardino, MD, FACS
4:20 – 4:50 pm State of ART Lecture Arie Belldegrun, MD, FACS Innovative Drug Development and the Academic Urologic Oncologist: A Personal Experience
MOUNTSINAIUROLOGYCME.ORG | 15 THIRD INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM • DECEMBER 13 – 15, 2018 NEW YORK, NY FRIDAY, DECEMBER 14 AFTERNOON SESSION: IMMUNOTHERAPY & TUMOR MICROENVIRONMENT, PART II MODERATORS: DANIEL PETRYLAK, MD AND JEFFREY BOCKMAN, PhD
1:05 pm – 1:35 pm How to Change the Field of Medicine Ralph Clayman, MD
1:35 pm – 1:40 pm Q&A How to Change the Field of Medicine
1:40 pm – 1:50 pm Biomarkers and Immunotherapy Susan F. Slovin, MD, PhD
1:50 pm – 2:00 pm Immunotherapy in Prostate Cancer James Gulley, MD, PhD
2:00 pm – 2:05 pm Q&A Immunotherapy in Prostate Cancer
2:05 pm – 2:20 pm The Online Urologist: From Separating Signal Noise in Nate Gross, MD Keeping with Research, to Boosting Referrals, Social, Mobile, and Machine Learning Technologies are Transforming Medicine
2:20 pm – 2:23 pm Q&AThe Online Urologist: From Separating Signal Noise in Keeping with Research, to Boosting Referrals, Social, Mobile, and Machine Learning Rechnologies are Tansforming Medicine
DEBATE 2:23 pm – 2:53 pm James Gulley v. Ravi Madan
PANELISTS Sexual Health Following Prostatectomy TBD
2:53 pm – 3:08 pm Orgasmic Dysfunction Following RARP Atsushi Takenaka, MD, PhD
Pending Presentations
Closing Remarks Ash Tewari, MBBS. MCh
1:05 pm – 1:15 pm Management of Incontinence After Radiation or Surgery Rajveer Purohit, MD
1:15 pm – 1:18 pm Q&A Management of Incontinence After Radiation or Surgery
1:18 pm – 1:28 pm Gene-Oncogene Interactions Carlos Cordon Cardo, MD, PhD
1:28 pm – 1:31 pm Q&A Gene-Oncogene Interactions
1:31 pm – 1:41 pm Current Status of Immune Therapy for Prostate Cancer Daniel Petrylak, MD
1:41 pm – 1:44 pm Q&A Current Status of Immune Therapy for Prostate Cancer
Linking Scientific and Clinical Issues 1:44 pm – 1:54 pm Jeffrey Bockman, PhD to Commercial/Strategic Considerations
1:54 pm – 1: 57pm Q&A Linking Scientific and Clinical Issues to Commercial/Strategic Considerations
16 | MTSINAIUROLOGYCME.ORG DECEMBER 13 – 15, 2018 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS FRIDAY, DECEMBER 14 AFTERNOON SESSION: IMMUNOTHERAPY & TUMOR MICROENVIRONMENT, PART II MODERATORS: DANIEL PETRYLAK, MD AND JEFFREY BOCKMAN, PhD
Oligometastases and New Therapies for Bone Metastic 1:57 pm – 2:07 pm Alex Kirschenbaum, MD Prostate Cancer
2:07 pm – 2:10 pm Q&A Oligometastases and New Therapies for Bone Metastic Prostate Cancer
1:44 pm – 1:54 pm Linking Scientific and Clinical Issues Jeffrey Bockman, PhD to Commercial/Strategic Considerations
1:54 pm – 1: 57pm Q&A Linking Scientific and Clinical Issues to Commercial/Strategic Considerations
1:57 pm – 2:07 pm Oligometastases and New Therapies Alex Kirschenbaum, MD for Bone Metastic Prostate Cancer
2:07 pm – 2:10 pm Q&A Oligometastases and New Therapies for Bone Metastic Prostate Cancer
2:10 pm – 2:20 pm Novel Therapeutic Targeting of Advanced Cancer Natasha Kyprianou, MD
2:20 pm – 2:23 pm Q&A Novel Therapeutic Targeting of Advanced Cancer
Tumor Suppressor, PTEN’s Role in Prostate Cancer 2:23 pm – 2:33 pm Sait Ozturk, PhD Progression
2:33 pm – 2:36 pm Q&A Tumor Suppressor, PTEN’s Role in Prostate Cancer Progression
Urinary Adverse Events After Prostate Cancer Treatment (RP, 2:36 pm – 2:46 pm Jaspreet Sandhu, MD RT, etc.)
2:46 pm – 2:49 pm Q&A Urinary Adverse Events After Prostate Cancer Treatment (RP, RT, etc.)
2:49 pm – 2:59 pm Robotic Post Chemotherapy RPLND James Porter, MD
2:59 pm – 3:02 pm Q&A (Robotic Post Chemotherapy RPLND)
3:02 pm – 3:12 pm Science That Underlies Prostate Cancer Racial Disparity Isaac Powell, MD
3:12 pm – 3:15 pm Q&A Science That Underlies Prostate Cancer Racial Disparity
Teamwork and Safety Conversations to Prevent Wrong Site 3:15 pm – 3:25 pm Amanda Rhee, MD Surgery
3:25 pm – 3:28 pm Q&A Teamwork and Safety Conversations to Prevent Wrong Site Surgery
3:28 pm – 3:38 pm Socioeconomic Implications of Prostate Cancer Therapy Deepak Kapoor, MD
3:38 pm – 3:41 pm Q&A Socioeconomic Implications of Prostate Cancer Therapy
MOUNTSINAIUROLOGYCME.ORG | 17 THIRD INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM • DECEMBER 13 – 15, 2018 NEW YORK, NY SATURDAY, DECEMBER 15 MORNING AGENDA
7:00 am –7:10 am Day Three Welcome Ketan Badani, MD
MODERATORS Session I: Upper Tract Disease Stern Auditorium John Sfakianos, MD and Chandru Sundaram, MD
EXPERT PANEL Daniel Eun, MD, Jonathan Coleman, MD, Doug Scherr, MD, Bobby Liaw, MD
7:10 am – 7:20 am Endoscopic Management Mantu Gupta, MD
7:20 am – 7:30 am Endourology for TCC John Denstedt, MD, FRCSC, FACS, FCAHS Contemporary Management of Upper Tract Urothelial 7:30 am – 7:45 am Jonathan Coleman, MD Cancer
Radical Nephroureterectomy with Robotic Assistance: 7:45 am – 8:00 am Ashok Hemal, MD Should It Be Standard Care? 8:00 am – 8:15 am Firefly and Upper Tract Reconstruction Daniel Eun, MD
8:15 am – 8:25 am Q&A Firefly and Upper Tract Reconstruction
MODERATORS Session II: Kidney I – Partial Nephrectomy Stern Auditorium Michael Palese, MD, Jamie Landman, MD
EXPERT PANEL Ralph Clayman, MD, Reza Ghavamian, MD James Porter, MD, Jim Hu, MD 8:25 am – 8:40 am New Technology in the O.R. Alex Mottrie, MD Fluorescence Imaging During Robotic Partial 8:40 am – 8:55 am Ronney Abaza, MD, FACS Nephrectomy for Margin Assessment 8:55 am – 9:10 am Complex Partial Nephrectomy Renorrhaphy Daniel Eun, MD Robotic Retroperitoneal Partial Nephrectomy OR 9:10 am – 9:25 am Transitioning from the Davinci Si to Xi for Partial Jim Porter, MD Nephrectomy
9:35 am – 10:00 am Break/Visit Exhibits
SURGEON 10:00 am – 11:30 am 3D Live Surgery: Robot Assisted Partial Nephrectomy Ketan Badani, MD
MODERATORS Ash Tewari, MBBS, MCh, Ashok Hemal, MD
PANELISTS Daniel Eun, MD, FRCS, Jihad Kaouk, MD, Francesco Porpiglia, MD, Ronney Abaza, MD
MODERATOR 11:30 am – 12:00 pm Complex Case Discussion Chandru Sundaram, MD PANELISTS Ketan Badani, MD, Alex Motzer, MD, Jihad Kaouk, MD, Ronney Abaza, MD
12:00 pm – 1:00 pm Lunch Sponsor TBD
18 | MTSINAIUROLOGYCME.ORG DECEMBER 13 – 15, 2018 NEW YORK, NY EXHIBITOR & PROMOTIONAL PARTNERSHIP PROSPECTUS SATURDAY, DECEMBER 15 AFTERNOON AGENDA
MODERATORS Session III: Kidney Cancer II Stern Auditorium Che-Kai Tsao, MD and Michael Stifleman, MD
EXPERT PANEL Robert Motzer, MD, Jamie Landman, MD, and Reza Ghavamian, MD, Badrinath Konety, MD Establishing Office Based Renal Mass Biopsy 1:00 pm - 1:15 pm Jaime Landman, MD into Urologic Oncology Practice Robotic Partial Nephrectomy for Tumors with Sinus Fat 1:15 pm – 1:30 pm Invasion: How to Preserve the Kidney with Negative Jihad Kaouk, MD Margins? Renal Function After Partial Nephrectomy – 1:30 pm – 1:45 pm Dipen Parkeh, MD Is Renal Ischemia Important?
1:45 pm – 2:00 pm Selective Clamping: How and Why Michael Stifleman, MD
2:00 pm – 2:15 pm Lecture Ketan Badani, MD
2:15pm – 2:25pm Q&A
Changing Landscape of Treatment in Metastatic Renal Cell 2:25 pm – 2:35 pm Che-Kai Tsao, MD Carcinoma Role of VEGF TKIs and Immunotherapy 2:35 pm – 2:50 pm Robert Motzer, MD for Advanced Kidney Cancer
MODERATOR 2:50 pm – 3:20 pm Debate: Oligometastatic Renal Cell Carcinoma TBD
Surgery First or Systemic Therapy First? DEBATER TBD
3:20 pm – 3:30 pm Break
MODERATORS Session IV: Bladder Cancer I Stern Auditorium John Sfakianos, MD and Michael Droller, MD
EXPERT PANEL Mark Schoenberg, MD, Alvin Goh, MD, and Michael Cookson, MD, Rene Javier Sotelo, MD
3:30 pm – 3:55 pm Semi Live Surgery: Robot Assisted Radical Cystectomy Peter Wiklund, MD, PhD
3:55 pm – 4:10 pm New Clinical Trial Designs in Urothelial Carcinoma Bishoy Faltas, MD
4:10 pm – 4:25 pm Zero Narcotic Protocol for Robotic Cystectomy: Surgical John Sfakianos, MD and and Anesthesia Considerations Alan Sim, MD Standardizing Trading with a “Top Down Approach”: 4:25 pm – 4:40 pm Justin Collins, MBChB, MD, FRCS Conclusions from a Train the Trainer Delphi Process
4:40 pm – 4:50 pm Q&A
MOUNTSINAIUROLOGYCME.ORG | 19 THIRD INTERNATIONAL PROSTATE CANCER AND UROLOGIC ONCOLOGY SYMPOSIUM • DECEMBER 13 – 15, 2018 NEW YORK, NY SATURDAY, DECEMBER 15 EVENING AGENDA
MODERATORS Session V: Bladder Cancer II Stern Auditorium Reza Mehrazin, MD and Bishoy Faltas, MD
EXPERT PANEL Doug Scherr, MD, Michael Droller, MD Erik Goluboff, MD Biomarkers Associated with Response and Resistance 4:50 pm – 5:05 pm Matthew Galsky, MD to Immune Checkpoint Blockade in Urothelial Cancer Do All Patients with Muscle Invasive Bladder Cancer 5:05 pm – 5:15 pm Require Neoadjuvant Chemotherapy? Hugh Lavery, MD A Review of Evidence
5:15 pm – 5:30 pm Bladder Cancer Patients Treated with Ipilimumb: Sacha Gnjatic, PhD Identifying Neoantigen-Specific T-Cell Responses
5:30 pm – 5:45 pm Pending Doug Scherr, MD
Bladder Cancer Health Services: 5:45 pm – 5:55 pm Nikhil Waingankar, MD Implications of the Volume-Outcome Effect
5:55 pm – 6:05 pm Q&A
Primary Non-Surgical Ablative Therapy 6:05 pm – 6:20 pm Mark Schoenberg, MD for Non-Invasive Urothelial Cancer Radical Cystectomy 6:20 pm – 6:30 pm Reza Mehrazin, MD for Non-Muscle Invasive Urothelial Carcinoma Intracorporeal Urinary Diversion 6:30 pm – 6:45 pm Alvin Goh, MD for Robotic Radical Cystectomy
6:45 pm – 6:50 pm End of Symposium Conclusion Ash Tewari, MBBS, MCh
20 | MTSINAIUROLOGYCME.ORG